March 22, 2017 / 11:27 AM / 7 months ago

BRIEF-Aveo announces first patient dosed in phase 1/2 tinivo trial

March 22 (Reuters) - Aveo Pharmaceuticals Inc:

* Aveo announces first patient dosed in phase 1/2 tinivo trial of tivozanib and opdivo (nivolumab) in advanced RCC

* Aveo Pharmaceuticals Inc - phase 1 trial will evaluate safety of tivozanib in combination with nivolumab at escalating doses of tivozanib

* Aveo Pharmaceuticals Inc - look forward to initial results from phase 1 portion of tinivo trial in first half of 2017 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below